Novo Nordisk (0QIU) Risk Analysis
Risk Overview Q4, 2025
Source: the company's latest filing for the period ended Dec 31, 2025, filed Feb 04, 2026
Risk Change Over Time
- Debt & Financing - Risk 1Capital expenditure in 2025, 2024 and 2023
For capital expenditure in 2025, 2024 and 2023, reference is made to the section entitled ‘Cash flow and capital allocation' on page 16 of our Annual Report 2025. No significant divestments took place in the period from 2023–2025. For capital expenditures expected in 2026, reference is made to pages 16-18 in the subsection ‘2026 outlook' in our Annual Report 2025. Such expenditures are expected to be financed with cash flow from operating activities.
- Corporate Activity and Growth - Risk 2C. Organisational structure
For information regarding the organisational structure and securities exchange listings of Novo Nordisk A/S, the controlling shareholder Novo Holdings A/S and the Novo Nordisk Foundation and the ownership structure of Novo Nordisk A/S, reference is made to the sections ‘Corporate Governance' on pages 39-40 and ‘Shares and capital structure' on pages 18-19 of our Annual Report 2025. Companies in the Novo Nordisk Group are listed in the section ‘Companies in the Novo Nordisk Group' on page 113 of our Annual Report 2025.
Risk Highlights Q4, 2025
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 17
- Share Price & Shareholder Rights - Risk 1Public takeover offers in respect of the Company's shares
No such offers occurred during 2025 or 2026 to date.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.